(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 2.37% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 5.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 121.37%.
Maxcyte's revenue in 2025 is $35,754,000.On average, 2 Wall Street analysts forecast MXCT's revenue for 2025 to be $3,901,803,317, with the lowest MXCT revenue forecast at $3,880,481,987, and the highest MXCT revenue forecast at $3,923,124,646.
In 2026, MXCT is forecast to generate $4,418,845,560 in revenue, with the lowest revenue forecast at $4,349,551,238 and the highest revenue forecast at $4,488,139,881.